134002-26-9

Basic information

• Product Name: 3-(S)-(+)-(1-Carbamoyl-1,1-diphenylmethyl)pyrroloidine-L-(+)-tartarate
• Synonyms: (S)--Diphenyl-3-pyrrolidine acetamide L-Tartaric Acid Salt;(S)-alpha,alpha-Diphenyl-3-pyrrolidineacetamide L-tartaric acid salt;Darifenacin Intermediate 5;(S)-α,α-Diphenyl-3-pyrrolidine acetamide L-Tartaric;Darifenacin Intermediate 8;(S)-Alpha,Alphal-Diphenyl-3-Pyrrolidineacetamide tartrate;3-(S)-(+)-(1-Carbamoyl-1,1-diphenylmethyl)pyrroloidine-L-(+)-tartarate;(S)-Alpha,Alpha-Diphenyl-3-Pyrrolidine Acetamide-L-Tartrate
• CAS NO: 134002-26-9
• Molecular Formula: C22H26N2O7
• Molecular Weight: 430.45104
• EINECS: 1312995-182-4
• Product Categories: Pharmaceutical material and intermeidates;INTERMEDIATESOFDARIFENACIN;API intermediates;Benzenes
• Mol File: 134002-26-9.mol
• Article Data: 9

Chemical Properties

• Appearance: White powder
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: DMSO (Slightly), Water (Slightly)
• CAS DataBase Reference: 3-(S)-(+)-(1-Carbamoyl-1,1-diphenylmethyl)pyrroloidine-L-(+)-tartarate(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(S)-(+)-(1-Carbamoyl-1,1-diphenylmethyl)pyrroloidine-L-(+)-tartarate(134002-26-9)
• EPA Substance Registry System: 3-(S)-(+)-(1-Carbamoyl-1,1-diphenylmethyl)pyrroloidine-L-(+)-tartarate(134002-26-9)

Safety Data

• Hazardous Substances Data: 134002-26-9(Hazardous Substances Data)

Usage

Uses

(S)-α,α-Diphenyl-3-pyrrolidineacetamide is an impurity arising in the synthesis of Darifenacin (D193500). It can also be used as muscarinic receptor antagonist.

InChI:InChI=1/C18H20N2O.C4H6O6/c19-17(21)18(16-11-12-20-13-16,14-7-3-1-4-8-14)15-9-5-2-6-10-15;5-1(3(7)8)2(6)4(9)10/h1-10,16,20H,11-13H2,(H2,19,21);1-2,5-6H,(H,7,8)(H,9,10)/t16-;1-,2-/m11/s1

Upstream product

• 134002-25-8 2,2-diphenyl-2-[(3S)-pyrrolidin-3-yl]acetamide 
• 87-69-4 L-Tartaric acid 
• 133099-11-3 (S)-2,2-diphenyl-2-(pyrrolidin-3-yl)-acetonitrile 
• 1189753-52-3 (S)-2,2-diphenyl-2-[1-(tert-butyloxycarbonyl)-3-pyrrolidinyl]acetonitrile 
• 87-69-4 tartaric acid 

Downstream Products

• 586346-94-3 darifenacin hydrochloride 

Relevant articles and documents

A new solvent system (Cyclopentyl methyl ether-water) in process development of darifenacin HBr

Darifenacin is a potent and competitive M3 selective receptor antagonist (M3SRA), and its hydrobromide salt (1) is the active ingredient of pharmaceutical formulations for oral treatment of urinary incontinence. The present work demonstrates an efficient, commercial manufacturing process for darifenacin hydrobromide (1).

PROCESS FOR PREPARING 3-SUBSTITUTED PYRROLIDINE COMPOUNDS

Disclosed is a process for preparing 3 -substituted pyrrolidine compounds of formula (VII) or salts thereof, wherein R1 is described herein, which are intermediate compounds useful for the synthesis of darifenacin which is indicated for the treatment of overactive bladder with symptoms of urge, urinary incontinence, and the like, and pharmaceutically acceptable salts thereof. Also disclosed is a process for preparing darifenacin and pharmaceutically acceptable salts thereof.

Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists

The invention provides compounds of formula I: in salt or zwitterionic form or a pharmaceutically acceptable salt thereof, wherein R1-6, a-e and Q are as defined in the specification. These compounds are muscarinic receptor antagonists. The inv